Over 100 companies race to develop 120+ new non-small cell lung cancer drugs globally

The global non-small cell lung cancer (NSCLC) drug development landscape is highly competitive, with over 100 companies working on more than 120 pipeline drugs. Key players include Pfizer, BioNTech, Merck, AstraZeneca, and others, focusing on innovative therapies such as targeted agents, immunotherapies, and antibody-drug conjugates. Recent regulatory approvals and designations by the FDA and EMA highlight progress, with several drugs in late-stage trials promising improved treatment options. This intense clinical trial activity signals a shift toward more personalized and effective NSCLC treatments in the near future.